Remove tag injectables
article thumbnail

What you need to know about treating skin tags

The Checkup by Singlecare

Skin tags are one of those things you probably don’t think about until you spot one. At first glance, you may fear it’s a symptom of psoriasis , eczema , HPV warts, or skin cancer —but skin tags are common, noncancerous, and essentially harmless. Read on to see what experts say about the following 13 home remedies for skin tags.

FDA 115
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PharmaShots Weekly Snapshots (May 01 - 05, 2023)

PharmaShots

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Date: May 05, 2023 | Tags: Chiesi Global Rare Diseases, Protalix BioTherapeutics, PRX-102, pegunigalsidase alfa, Fabry Disease, Regulatory, EC, Marketing Authorization Kinoxis Therapeutics (..)

FDA 40
article thumbnail

What states use Ozempic the most?

The Checkup by Singlecare

The #ozempic tag on TikTok has amassed over 1 billion views to date. If the injectable medication is prescribed for weight loss, many insurance providers won’t cover it (or its weight-loss counterpart Wegovy )—which is where SingleCare comes in and why people are filling the medication with our coupons.

Insurance 105
article thumbnail

ASH: Argenx cues up a second use for efgartigimod

pharmaphorum

Vyvgart is already approved to treat generalised myasthenia gravis, getting a green light for that indication from the FDA a year ago, and launched with a $225,000 per annum price tag in competition with rival gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).

article thumbnail

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

pharmaphorum

The agreement has been hailed by patient associations, as it adds to current treatment options for the progressive muscle wasting disease – Biogen’s injectable Spinraza (nusinersen) and one-shot gene therapy with Novartis’ Zolgensma (onasemnogene abeparvovec) – which are also backed by NICE.

97
article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based